| name | Levonorgestrel-containing intrauterine system (IUS) |
| Classification | Long-acting reversible contraceptive (LARC) |
| Pharmacokinetics | Levonorgestrel is released slowly from the IUS into the uterus. High local concentrations of the hormone suppress ovulation. The exact pharmacokinetic profile for an individual patient can vary. |
| suggested dosage | Single insertion by a healthcare provider; no ongoing dose adjustments. |
| indications | Long-term reversible contraception for patients desiring a reliable and low-maintenance method. |
| safety in pregnancy | Contraindicated if pregnancy is suspected or confirmed. |
| safety in breastfeeding | Generally safe during breastfeeding, with minimal impact on breast milk composition. |
| side effects | | 1 | Spotting or bleeding irregularities (amenorrhea, spotting, or breakthrough bleeding) | | 2 | Acne | | 3 | Headaches | | 4 | Mood changes | | 5 | Breast tenderness | | 6 | Pelvic pain | | 7 | Weight fluctuations (small, variable changes) |
|
| alternatives | |
| contraindications | | 1 | Known or suspected pregnancy | | 2 | Unexplained vaginal bleeding | | 3 | Pelvic inflammatory disease | | 4 | Known or suspected uterine abnormalities | | 5 | History of ectopic pregnancy |
|
| interactions | Limited drug-drug interactions. No significant interactions documented for common medications. Consult with healthcare provider for any specific concerns. |
| warnings and precautions | | 1 | Risk of expulsion, perforation, or infection following insertion. | | 2 | Proper follow-up and examination by a physician are necessary. | | 3 | Increased risk of pelvic inflammatory disease, though infrequent. | | 4 | Potential for pain or discomfort during the procedure. |
|
| additional informations | Insertion performed by a healthcare professional. Patients should be aware of potential spotting/bleeding irregularities in first few months. A thorough evaluation and discussion of risks/benefits by the physician is imperative. |
| patient specific considerations | Age and weight (not significant factors in determining suitability). Individual risk factors and medical history should be considered. |
| duration of action | Long-term (effective for 3-7 years depending on type of IUS or implant) |
